Trial Profile

A Phase Ib/II, Single-arm, Multi-center Clinical Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Toripalimab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

Most Recent Events

04 Aug 2026 Actual primary completion date changed from 30 Nov 2022 to 25 Oct 2024.
04 Aug 2026 Status changed from recruiting to completed.
07 Jun 2022 Preliminary results of the phase Ib portion presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com